Johnson & Johnson’s first quarter revenue missed Wall Street estimates on Tuesday with sales of its blockbuster psoriasis drug Stelara coming in lower than expected as the company prepares for its loss of exclusivity in the United States.
Tag Archive for: psoriasis
The company forecasted revenue growth of 5-6% for the next year, as it banks on strong demand for cancer treatments Darzalex and Carvykti and resilient sales of blockbuster drug Stelara.
BMS pushed back by a year the time frame for its current new-product portfolio to hit $10 billion in sales as the ramp-up of new drugs including anemia treatment Reblozyl, psoriasis drug Sotyktu, and multiple sclerosis drug Zeposia takes longer than expected.
Eli Lilly and Co. agreed to buy Dice Therapeutics Inc. for about $2.4 billion in cash on Tuesday, bolstering its immune disease-related portfolio with a largely oral drug developer.
Johnson & Johnson’s legal settlement with Amgen to delay a biosimilar version of its blockbuster psoriasis treatment Stelara until January 2025 could make the drug a larger contributor to J&J’s 2024 and 2025 sales than Wall Street is forecasting.
Last year CDER approved 37 new drugs never before approved or marketed in the U.S., known as “novel” drugs, as noted in its annual New Drug Therapy Approvals report. The agency also approved drugs in new settings, such as for new uses and patient populations.
The company said it would acquire Nimbus Therapeutics’ drug being developed to treat autoimmune conditions such as psoriasis in up to $6 billion deal.
Amgen is equipped with a broad and diverse product portfolio, commercial capabilities, and levers for delivering mid-single digit revenue growth over this decade.
Novartis said its anti-inflammatory drug Cosentyx eased the symptoms of a painful, lump-forming skin condition in two late-stage trials, putting the approved treatment on track to further shore up sales growth at the Swiss drugmaker.
The U.S. Food and Drug Administration’s calendar for PDUFA dates is relatively quiet for the middle of July, although it picks up heading into August. Here’s a look at target action dates for the next two weeks.